Latest News Archive
Please select Category, Year, and then Month to display items
17 August 2020
|
Story Nitha Ramnath
|
Photo istock
Within the next five years, 60% of the world’s population will be living in urban areas. Urban living comes with large-scale economic advantages and society benefits from economies of scale. But, COVID-19 is challenging urban living. We have introduced the term ‘social distancing’ and some policy analysts have even argued for the de-densification of cities.
Join us for a discussion where our panellists will analyse this perceived conflict.
Date: Thursday, 27 August 2020
Time: 14:00 to 15:30 (South African Standard Time – GMT +2)
Please RSVP to Elelwani Mmbadi at
mmbadiE@ufs.ac.za no later than 25 August, upon which you will receive a Skype for Business meeting invite and link to access the webinar.
Speakers:
Prof Ivan Turok
Dr Geci Karuri-Sebina
Mr Thiresh Govender
Moderator:
Lochner Marais
UFS to monitor the use of ARV-drugs on pregnant women and children
2004-12-08
The University of the Free State (UFS) is to establish a Pharmacovigilance Centre that will monitor the effects of Anti-Retroviral (ARV) drugs on HIV positive pregnant women and children starting early in the new year.
The UFS is one of only two institutions chosen by the Minister of Health, Dr Manto Tshabalala-Msimang, to establish such an ARV monitoring centre.
The other centre will be based at Medical University of South Africa (MEDUNSA) and will concentrate mainly on monitoring the effects of the drugs on adults.
“The establishment of the UFS’s Pharmaconvigilance Centre forms part of government’s Comprehensive Plan on HIV and AIDS, often termed the roll-out plan for ARV drugs. The centre’s primary responsibility will be to specifically monitor the use of these drugs in pregnant women, and children under the age of 13,” said Prof Andrew Walubo of the UFS’s Department of Pharmacology.
“Although most of the side effects of ARV drugs have been identified in other countries, it has now become critical to identify the side effects amongst the South African population. This is important because many people will be exposed to the drugs within a short time. Our aim is so identify the most common side effects and make recommendations for the prevention thereof. The centre will help in detecting the risk of using anti-retroviral drugs in pregnancy and children, and prevention of adverse drug reactions,” said Prof Walubo.
According to Prof Walubo 12 drugs will be monitored – these drugs will be selected according to the patient’s profile.
The centre will comprise of two components: A pregnancy registry, which will focus on a new-born child up until two months and a pediatric registry, which will focus on children who are born of mothers who used ARV drugs and children using ARV drugs.
According to Prof Walubo, the Pharmaconvigilance Centre will also be responsible for offering relevant technical advice, training and selected research on ARV drugs in these patients.
The centre will be fully sponsored by the national Department of Health. It will be based in the UFS’s Faculty of Health Sciences, Department of Pharmacology, and will be run in collaboration with experts from different departments in the faculty.
Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
E-mail: loaderl.stg@mail.uovs.ac.za
8 December 2004